Rituximab Promotes Long-Term Response for Patients with Immune Destruction of ... MarketWatch (press release) WASHINGTON, May 7, 2012 /PRNewswire via COMTEX/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet ... |
